VIM
NBIX icon

Vinva Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Vinva Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.8M Buy
346,109
+271,013
+361% +$40.2M 0.39% 66
2026
Q1 		$9.67M Buy
75,096
+369
+0.5% +$49K 0.12% 178
2025
Q4 		$10.5M Buy
74,727
+67,951
+1,003% +$9.84M 0.13% 156
2025
Q3 		$950K Buy
6,776
+1,691
+33% +$229K 0.02% 325
2025
Q2 		$638K Buy
5,085
+336
+7% +$38.5K 0.02% 339
2025
Q1 		$537K Sell
4,749
-8,542
-64% -$1.08M 0.02% 324
2024
Q4 		$1.82M Sell
13,291
-25,249
-66% -$3.12M 0.07% 236
2024
Q3 		$4.43M Buy
38,540
+21,795
+130% +$2.99M 0.19% 126
2024
Q2 		$2.25M Buy
16,745
+10,266
+158% +$1.41M 0.11% 191
2024
Q1 		$894K Buy
6,479
+1,678
+35% +$229K 0.05% 299
2023
Q4 		$634K Buy
4,801
+650
+16% +$74.8K 0.04% 311
2023
Q3 		$478K Sell
4,151
-1,063
-20% -$112K 0.04% 299
2023
Q2 		$493K Sell
5,214
-9,215
-64% -$900K 0.04% 306
2023
Q1 		$1.43M Buy
+14,429
New +$1.5M 0.12% 196

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vinva Investment Management's NBIX Position: Q2 2026 in Review

Vinva Investment Management increased its Neurocrine Biosciences (NBIX) stake by 361% in Q2 2026, buying an estimated $40.2M and bringing the position to 346,109 shares worth $58.8M. The position accounts for 0.39% of the portfolio, ranked #66.

Vinva Investment Management first reported a position in NBIX in Q1 2023 and has held it in 14 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Vinva Investment Management held 346,109 shares of Neurocrine Biosciences worth $58.8M as of Q2 2026.
  • Vinva Investment Management bought 271,013 Neurocrine Biosciences shares in Q2 2026, an estimated $40.2M.
  • Neurocrine Biosciences made up 0.39% of Vinva Investment Management's portfolio in Q2 2026, its #66 holding.
  • Vinva Investment Management first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 14 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Vinva Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.